Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery.

fibrosis glaucoma glaucoma surgery intraocular pressure

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
19 Jun 2023
Historique:
received: 16 04 2023
revised: 15 05 2023
accepted: 12 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Glaucoma is an acquired optic neuropathy that results in a characteristic optic nerve head appearance and visual field loss. Reducing the IOP is the only factor that can be modified, and the progression of the disease can be managed through medication, laser treatment, or surgery. Filtering procedures are used when target pressure cannot be obtained with less invasive methods. Nevertheless, these procedures require accurate control of the fibrotic process, which can hamper filtration, thus, negatively affecting the surgical success. This review explores the available and potential pharmacological treatments that modulate the scarring process after glaucoma surgery, analyzing the most critical evidence available in the literature. The modulation of scarring is based on non-steroidal anti-inflammatory drugs (NSAIDs), mitomycin, and 5-fluorouracil. In the long term, the failure rate of filtering surgery is mainly due to the limitations of the current strategies caused by the complexity of the fibrotic process and the pharmacological and toxicological aspects of the drugs that are currently in use. Considering these limitations, new potential treatments were investigated. This review suggests that a better approach to tackle the fibrotic process may be to hit multiple targets, thus increasing the inhibitory potential against excessive scarring following surgery.

Identifiants

pubmed: 37375845
pii: ph16060898
doi: 10.3390/ph16060898
pmc: PMC10305204
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Cutan Ocul Toxicol. 2022 Mar;41(1):25-32
pubmed: 34749555
Cells. 2020 Oct 27;9(11):
pubmed: 33121103
Vet Ophthalmol. 2017 Sep;20(5):398-404
pubmed: 27791324
Indian J Ophthalmol. 2016 Mar;64(3):251-2
pubmed: 27146944
Acta Ophthalmol. 2019 Mar;97(2):146-157
pubmed: 30242968
Expert Opin Biol Ther. 2018 Jun;18(6):719-724
pubmed: 29781319
Graefes Arch Clin Exp Ophthalmol. 2022 Sep;260(9):2981-2990
pubmed: 35348842
Nanomaterials (Basel). 2020 Apr 10;10(4):
pubmed: 32290252
Anticancer Agents Med Chem. 2022;22(5):978-990
pubmed: 34126912
Nippon Ganka Gakkai Zasshi. 1992 Apr;96(4):455-61
pubmed: 1621583
Ophthalmology. 2007 Oct;114(10):1822-30
pubmed: 17908591
Dtsch Arztebl Int. 2020 Mar 27;117(13):225-234
pubmed: 32343668
Clin Ophthalmol. 2015 Oct 20;9:1945-51
pubmed: 26527859
Cochrane Database Syst Rev. 2015 Nov 06;(11):CD006259
pubmed: 26545176
Am J Physiol Cell Physiol. 2022 Mar 1;322(3):C554-C566
pubmed: 35171698
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Prostaglandins Other Lipid Mediat. 2021 Oct;156:106578
pubmed: 34245897
J Am Chem Soc. 2019 Jul 10;141(27):10760-10769
pubmed: 31185171
BMC Ophthalmol. 2016 May 26;16:65
pubmed: 27230388
BMC Ophthalmol. 2016 Mar 05;16:24
pubmed: 26946419
Science. 1990 Aug 3;249(4968):505-10
pubmed: 2200121
Acta Ophthalmol. 2015 Nov;93(7):667-78
pubmed: 25988844
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD003433
pubmed: 22696336
Acta Ophthalmol. 2022 Nov;100(7):740-751
pubmed: 35088941
Nat Biotechnol. 2011 Apr;29(4):325-6
pubmed: 21478846
Vestn Oftalmol. 2022;138(4):136-143
pubmed: 36004602
J Glaucoma. 2016 Mar;25(3):e145-9
pubmed: 25493620
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71
pubmed: 2424019
Curr Opin Ophthalmol. 2021 Mar 1;32(2):148-159
pubmed: 33315724
Exp Eye Res. 2011 Nov;93(5):689-99
pubmed: 21907194
Drug Des Devel Ther. 2014 May 02;8:421-9
pubmed: 24851041
Int J Ophthalmol. 2022 May 18;15(5):690-700
pubmed: 35601180
Ophthalmol Ther. 2017 Dec;6(2):323-334
pubmed: 28669026
Int J Pharm. 2020 Feb 15;575:118943
pubmed: 31830575
Lancet. 1999 Dec 4;354(9194):1932-9
pubmed: 10622295
Matrix Biol. 2021 Mar;97:1-19
pubmed: 33582236

Auteurs

Debora Collotta (D)

Department of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.

Simona Colletta (S)

Department of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.

Virginia Carlucci (V)

Chemsafe S.r.l., Via Ribes 5, 10010 Colleretto Giacosa, Italy.

Claudia Fruttero (C)

Hospital Pharmacy, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.

Antonio Maria Fea (AM)

Struttura Complessa Oculistica, Città Della Salute e Della Scienza di Torino, Dipartimento di Scienze Chirurgiche, Università degli Studi di Torino, 10126 Torino, Italy.

Massimo Collino (M)

Department of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.

Classifications MeSH